Janina S. Ried
University of Washington
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Janina S. Ried.
Nature Communications | 2015
Beben Benyamin; Tonu Esko; Janina S. Ried; Aparna Radhakrishnan; Sita H. Vermeulen; Michela Traglia; Martin Goegele; Denise Anderson; Linda Broer; Clara Podmore; Jian'an Luan; Zoltán Kutalik; Serena Sanna; Peter van der Meer; Toshiko Tanaka; Fudi Wang; Harm-Jan Westra; Lude Franke; Evelin Mihailov; Lili Milani; Jonas Haelldin; Juliane Winkelmann; Thomas Meitinger; Joachim Thiery; Annette Peters; Melanie Waldenberger; Augusto Rendon; Jennifer Jolley; Jennifer Sambrook; Lambertus A. Kiemeney
Corrigendum: Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis
Nature | 2011
Karsten Suhre; So-Youn Shin; Ann-Kristin Petersen; Robert P. Mohney; David Meredith; Brigitte Wägele; Elisabeth Altmaier; Panos Deloukas; Jeanette Erdmann; Elin Grundberg; Christopher J. Hammond; Martin Hrabé de Angelis; Gabi Kastenmüller; Anna Köttgen; Florian Kronenberg; Massimo Mangino; Christa Meisinger; Thomas Meitinger; Hans-Werner Mewes; Michael V. Milburn; Cornelia Prehn; Johannes Raffler; Janina S. Ried; Werner Römisch-Margl; Nilesh J. Samani; Kerrin S. Small; H.-Erich Wichmann; Guangju Zhai; Thomas Illig; Tim D. Spector
Genome-wide association studies (GWAS) have identified many risk loci for complex diseases, but effect sizes are typically small and information on the underlying biological processes is often lacking. Associations with metabolic traits as functional intermediates can overcome these problems and potentially inform individualized therapy. Here we report a comprehensive analysis of genotype-dependent metabolic phenotypes using a GWAS with non-targeted metabolomics. We identified 37 genetic loci associated with blood metabolite concentrations, of which 25 show effect sizes that are unusually high for GWAS and account for 10–60% differences in metabolite levels per allele copy. Our associations provide new functional insights for many disease-related associations that have been reported in previous studies, including those for cardiovascular and kidney disorders, type 2 diabetes, cancer, gout, venous thromboembolism and Crohn’s disease. The study advances our knowledge of the genetic basis of metabolic individuality in humans and generates many new hypotheses for biomedical and pharmaceutical research.
PLOS Genetics | 2011
Kirstin Mittelstrass; Janina S. Ried; Zhonghao Yu; Jan Krumsiek; Christian Gieger; Cornelia Prehn; Werner Roemisch-Margl; Alexey Polonikov; Annette Peters; Fabian J. Theis; Thomas Meitinger; Florian Kronenberg; Stephan Weidinger; Heinz Erich Wichmann; Karsten Suhre; Rui Wang-Sattler; Jerzy Adamski; Thomas Illig
Metabolomic profiling and the integration of whole-genome genetic association data has proven to be a powerful tool to comprehensively explore gene regulatory networks and to investigate the effects of genetic variation at the molecular level. Serum metabolite concentrations allow a direct readout of biological processes, and association of specific metabolomic signatures with complex diseases such as Alzheimers disease and cardiovascular and metabolic disorders has been shown. There are well-known correlations between sex and the incidence, prevalence, age of onset, symptoms, and severity of a disease, as well as the reaction to drugs. However, most of the studies published so far did not consider the role of sexual dimorphism and did not analyse their data stratified by gender. This study investigated sex-specific differences of serum metabolite concentrations and their underlying genetic determination. For discovery and replication we used more than 3,300 independent individuals from KORA F3 and F4 with metabolite measurements of 131 metabolites, including amino acids, phosphatidylcholines, sphingomyelins, acylcarnitines, and C6-sugars. A linear regression approach revealed significant concentration differences between males and females for 102 out of 131 metabolites (p-values<3.8×10−4; Bonferroni-corrected threshold). Sex-specific genome-wide association studies (GWAS) showed genome-wide significant differences in beta-estimates for SNPs in the CPS1 locus (carbamoyl-phosphate synthase 1, significance level: p<3.8×10−10; Bonferroni-corrected threshold) for glycine. We showed that the metabolite profiles of males and females are significantly different and, furthermore, that specific genetic variants in metabolism-related genes depict sexual dimorphism. Our study provides new important insights into sex-specific differences of cell regulatory processes and underscores that studies should consider sex-specific effects in design and interpretation.
Nature Genetics | 2015
Ida Surakka; Momoko Horikoshi; Reedik Mägi; Antti-Pekka Sarin; Anubha Mahajan; Vasiliki Lagou; Letizia Marullo; Teresa Ferreira; Benjamin Miraglio; Sanna Timonen; Johannes Kettunen; Matti Pirinen; Juha Karjalainen; Gudmar Thorleifsson; Sara Hägg; Jouke-Jan Hottenga; Aaron Isaacs; Claes Ladenvall; Marian Beekman; Tonu Esko; Janina S. Ried; Christopher P. Nelson; Christina Willenborg; Stefan Gustafsson; Harm-Jan Westra; Matthew Blades; Anton J. M. de Craen; Eco J. C. de Geus; Joris Deelen; Harald Grallert
Using a genome-wide screen of 9.6 million genetic variants achieved through 1000 Genomes Project imputation in 62,166 samples, we identify association to lipid traits in 93 loci, including 79 previously identified loci with new lead SNPs and 10 new loci, 15 loci with a low-frequency lead SNP and 10 loci with a missense lead SNP, and 2 loci with an accumulation of rare variants. In six loci, SNPs with established function in lipid genetics (CELSR2, GCKR, LIPC and APOE) or candidate missense mutations with predicted damaging function (CD300LG and TM6SF2) explained the locus associations. The low-frequency variants increased the proportion of variance explained, particularly for low-density lipoprotein cholesterol and total cholesterol. Altogether, our results highlight the impact of low-frequency variants in complex traits and show that imputation offers a cost-effective alternative to resequencing.
PLOS Genetics | 2010
Tamra E. Meyer; Germaine C. Verwoert; Shih-Jen Hwang; Nicole L. Glazer; Albert V. Smith; Frank J. A. van Rooij; Georg B. Ehret; Eric Boerwinkle; Janine F. Felix; Tennille S. Leak; Tamara B. Harris; Qiong Yang; Abbas Dehghan; Thor Aspelund; Ronit Katz; Georg Homuth; Thomas Kocher; Rainer Rettig; Janina S. Ried; Christian Gieger; Hanna Prucha; Arne Pfeufer; Thomas Meitinger; Josef Coresh; Albert Hofman; Mark J. Sarnak; Yii-Der I. Chen; André G. Uitterlinden; Aravinda Chakravarti; Bruce M. Psaty
Magnesium, potassium, and sodium, cations commonly measured in serum, are involved in many physiological processes including energy metabolism, nerve and muscle function, signal transduction, and fluid and blood pressure regulation. To evaluate the contribution of common genetic variation to normal physiologic variation in serum concentrations of these cations, we conducted genome-wide association studies of serum magnesium, potassium, and sodium concentrations using ∼2.5 million genotyped and imputed common single nucleotide polymorphisms (SNPs) in 15,366 participants of European descent from the international CHARGE Consortium. Study-specific results were combined using fixed-effects inverse-variance weighted meta-analysis. SNPs demonstrating genome-wide significant (p<5×10−8) or suggestive associations (p<4×10−7) were evaluated for replication in an additional 8,463 subjects of European descent. The association of common variants at six genomic regions (in or near MUC1, ATP2B1, DCDC5, TRPM6, SHROOM3, and MDS1) with serum magnesium levels was genome-wide significant when meta-analyzed with the replication dataset. All initially significant SNPs from the CHARGE Consortium showed nominal association with clinically defined hypomagnesemia, two showed association with kidney function, two with bone mineral density, and one of these also associated with fasting glucose levels. Common variants in CNNM2, a magnesium transporter studied only in model systems to date, as well as in CNNM3 and CNNM4, were also associated with magnesium concentrations in this study. We observed no associations with serum sodium or potassium levels exceeding p<4×10−7. Follow-up studies of newly implicated genomic loci may provide additional insights into the regulation and homeostasis of human serum magnesium levels.
Ophthalmology | 2015
Katie M. Williams; Geir Bertelsen; Phillippa M. Cumberland; Christian Wolfram; Virginie J. M. Verhoeven; Eleftherios Anastasopoulos; Gabriëlle H.S. Buitendijk; Audrey Cougnard-Grégoire; Catherine Creuzot-Garcher; Maja G. Erke; Ruth E. Hogg; René Höhn; Pirro G. Hysi; Anthony P. Khawaja; Jean-François Korobelnik; Janina S. Ried; Johannes R. Vingerling; Alain M. Bron; Jean-François Dartigues; Astrid E. Fletcher; Albert Hofman; Robert W. A. M. Kuijpers; Robert Luben; Konrad Oxele; Fotis Topouzis; Therese von Hanno; Alireza Mirshahi; Paul J. Foster; Cornelia M. van Duijn; Norbert Pfeiffer
Purpose To investigate whether myopia is becoming more common across Europe and explore whether increasing education levels, an important environmental risk factor for myopia, might explain any temporal trend. Design Meta-analysis of population-based, cross-sectional studies from the European Eye Epidemiology (E3) Consortium. Participants The E3 Consortium is a collaborative network of epidemiological studies of common eye diseases in adults across Europe. Refractive data were available for 61 946 participants from 15 population-based studies performed between 1990 and 2013; participants had a range of median ages from 44 to 78 years. Methods Noncycloplegic refraction, year of birth, and highest educational level achieved were obtained for all participants. Myopia was defined as a mean spherical equivalent ≤−0.75 diopters. A random-effects meta-analysis of age-specific myopia prevalence was performed, with sequential analyses stratified by year of birth and highest level of educational attainment. Main Outcome Measures Variation in age-specific myopia prevalence for differing years of birth and educational level. Results There was a significant cohort effect for increasing myopia prevalence across more recent birth decades; age-standardized myopia prevalence increased from 17.8% (95% confidence interval [CI], 17.6–18.1) to 23.5% (95% CI, 23.2–23.7) in those born between 1910 and 1939 compared with 1940 and 1979 (P = 0.03). Education was significantly associated with myopia; for those completing primary, secondary, and higher education, the age-standardized prevalences were 25.4% (CI, 25.0–25.8), 29.1% (CI, 28.8–29.5), and 36.6% (CI, 36.1–37.2), respectively. Although more recent birth cohorts were more educated, this did not fully explain the cohort effect. Compared with the reference risk of participants born in the 1920s with only primary education, higher education or being born in the 1960s doubled the myopia prevalence ratio–2.43 (CI, 1.26–4.17) and 2.62 (CI, 1.31–5.00), respectively—whereas individuals born in the 1960s and completing higher education had approximately 4 times the reference risk: a prevalence ratio of 3.76 (CI, 2.21–6.57). Conclusions Myopia is becoming more common in Europe; although education levels have increased and are associated with myopia, higher education seems to be an additive rather than explanatory factor. Increasing levels of myopia carry significant clinical and economic implications, with more people at risk of the sight-threatening complications associated with high myopia.
Journal of The American Society of Nephrology | 2010
Bryan Kestenbaum; Nicole L. Glazer; Anna Köttgen; Janine F. Felix; Shih Jen Hwang; Yongmei Liu; Kurt Lohman; Stephen B. Kritchevsky; Dorothy B. Hausman; Ann Kristin Petersen; Christian Gieger; Janina S. Ried; Thomas Meitinger; Tim M. Strom; H.-Erich Wichmann; Harry Campbell; Caroline Hayward; Igor Rudan; Ian H. de Boer; Bruce M. Psaty; Kenneth Rice; Yii-Der I. Chen; Man Li; Dan E. Arking; Eric Boerwinkle; Josef Coresh; Qiong Yang; Daniel Levy; Frank J. A. van Rooij; Abbas Dehghan
Phosphorus is an essential mineral that maintains cellular energy and mineralizes the skeleton. Because complex actions of ion transporters and regulatory hormones regulate serum phosphorus concentrations, genetic variation may determine interindividual variation in phosphorus metabolism. Here, we report a comprehensive genome-wide association study of serum phosphorus concentration. We evaluated 16,264 participants of European ancestry from the Cardiovascular Heath Study, Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and the Rotterdam Study. We excluded participants with an estimated GFR <45 ml/min per 1.73 m(2) to focus on phosphorus metabolism under normal conditions. We imputed genotypes to approximately 2.5 million single-nucleotide polymorphisms in the HapMap and combined study-specific findings using meta-analysis. We tested top polymorphisms from discovery cohorts in a 5444-person replication sample. Polymorphisms in seven loci with minor allele frequencies 0.08 to 0.49 associate with serum phosphorus concentration (P = 3.5 x 10(-16) to 3.6 x 10(-7)). Three loci were near genes encoding the kidney-specific type IIa sodium phosphate co-transporter (SLC34A1), the calcium-sensing receptor (CASR), and fibroblast growth factor 23 (FGF23), proteins that contribute to phosphorus metabolism. We also identified genes encoding phosphatases, kinases, and phosphodiesterases that have yet-undetermined roles in phosphorus homeostasis. In the replication sample, five of seven top polymorphisms associate with serum phosphorous concentrations (P < 0.05 for each). In conclusion, common genetic variants associate with serum phosphorus in the general population. Further study of the loci identified in this study may help elucidate mechanisms of phosphorus regulation.
Human Molecular Genetics | 2011
Konrad Oexle; Janina S. Ried; Andrew A. Hicks; Toshiko Tanaka; Caroline Hayward; M. Bruegel; Martin Gögele; Peter Lichtner; Bertram Müller-Myhsok; Angela Döring; Thomas Illig; Christine Schwienbacher; Cosetta Minelli; Irene Pichler; G. M. Fiedler; Joachim Thiery; Igor Rudan; Alan F. Wright; Harry Campbell; Luigi Ferrucci; Stefania Bandinelli; Peter P. Pramstaller; H-Erich Wichmann; Christian Gieger; Juliane Winkelmann; Thomas Meitinger
The level of body iron storage and the erythropoietic need for iron are indicated by the serum levels of ferritin and soluble transferrin receptor (sTfR), respectively. A meta-analysis of five genome-wide association studies on sTfR and ferritin revealed novel association to the PCSK7 and TMPRSS6 loci for sTfR and the HFE locus for both parameters. The PCSK7 association was the most significant (rs236918, P = 1.1 × 10E-27) suggesting that proprotein convertase 7, the gene product of PCSK7, may be involved in sTfR generation and/or iron homeostasis. Conditioning the sTfR analyses on transferrin saturation abolished the HFE signal and substantially diminished the TMPRSS6 signal while the PCSK7 association was unaffected, suggesting that the former may be mediated by transferrin saturation whereas the PCSK7-associated effect on sTfR generation appears to be more direct.
Diabetes Care | 2015
Tao Xu; Stefan Brandmaier; Ana C. Messias; Christian Herder; Harmen H. M. Draisma; Ayse Demirkan; Zhonghao Yu; Janina S. Ried; Toomas Haller; Margit Heier; Monica Campillos; Gisela Fobo; Renee Stark; Christina Holzapfel; Jonathan Adam; Shen Chi; Markus Rotter; Tommaso Panni; Anne S. Quante; Ying He; Cornelia Prehn; Werner Roemisch-Margl; Gabi Kastenmüller; Gonneke Willemsen; René Pool; Katarina Kasa; Ko Willems van Dijk; Thomas Hankemeier; Christa Meisinger; Barbara Thorand
OBJECTIVE Metformin is used as a first-line oral treatment for type 2 diabetes (T2D). However, the underlying mechanism is not fully understood. Here, we aimed to comprehensively investigate the pleiotropic effects of metformin. RESEARCH DESIGN AND METHODS We analyzed both metabolomic and genomic data of the population-based KORA cohort. To evaluate the effect of metformin treatment on metabolite concentrations, we quantified 131 metabolites in fasting serum samples and used multivariable linear regression models in three independent cross-sectional studies (n = 151 patients with T2D treated with metformin [mt-T2D]). Additionally, we used linear mixed-effect models to study the longitudinal KORA samples (n = 912) and performed mediation analyses to investigate the effects of metformin intake on blood lipid profiles. We combined genotyping data with the identified metformin-associated metabolites in KORA individuals (n = 1,809) and explored the underlying pathways. RESULTS We found significantly lower (P < 5.0E-06) concentrations of three metabolites (acyl-alkyl phosphatidylcholines [PCs]) when comparing mt-T2D with four control groups who were not using glucose-lowering oral medication. These findings were controlled for conventional risk factors of T2D and replicated in two independent studies. Furthermore, we observed that the levels of these metabolites decreased significantly in patients after they started metformin treatment during 7 years’ follow-up. The reduction of these metabolites was also associated with a lowered blood level of LDL cholesterol (LDL-C). Variations of these three metabolites were significantly associated with 17 genes (including FADS1 and FADS2) and controlled by AMPK, a metformin target. CONCLUSIONS Our results indicate that metformin intake activates AMPK and consequently suppresses FADS, which leads to reduced levels of the three acyl-alkyl PCs and LDL-C. Our findings suggest potential beneficial effects of metformin in the prevention of cardiovascular disease.
Allergy | 2013
Janina S. Ried; Hansjörg Baurecht; Ferdinand Stückler; Jan Krumsiek; Christian Gieger; Joachim Heinrich; Michael Kabesch; Cornelia Prehn; Annette Peters; Elke Rodriguez; H. Schulz; Konstantin Strauch; Karsten Suhre; Rui Wang-Sattler; H-Erich Wichmann; Fabian J. Theis; Thomas Illig; Jerzy Adamski; Stephan Weidinger
Genome‐wide association studies (GWAS) have identified many risk loci for asthma, but effect sizes are small, and in most cases, the biological mechanisms are unclear. Targeted metabolite quantification that provides information about a whole range of pathways of intermediary metabolism can help to identify biomarkers and investigate disease mechanisms. Combining genetic and metabolic information can aid in characterizing genetic association signals with high resolution. This work aimed to investigate the interrelation of current asthma, candidate asthma risk alleles and a panel of metabolites.